Senti Biosciences (SNTI) Appoints Fran Schulz to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Nasdaq climbs as chip and AI-linked stocks bounce back
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Brent crude edges lower, even after Houthi attacks on Saudi infrastructure
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
Senti Bio Appoints Fran Schulz to Board of Directors
December 2, 2024 7:00 AM ESTSOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (Senti Bio or the Company), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Fran Schulz, a highly experienced biotechnology and financial executive, to the Senti Bio Board of Directors (Board).
We are excited to welcome Fran to the Senti Bio Board of Directors, said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. Fran's deep expertise in the life sciences industryspanning finance, strategic planning,... More



